Literature DB >> 24847652

The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Hung-Ming Lam, Robert L Vessella, Colm Morrissey.   

Abstract

Disseminated tumor cells (DTC) leave the primary tumor and reside in distant sites (e.g. bone) early in prostate cancer. Patients may harbor dormant DTC which develop into clinically overt metastasis years after radical prostatectomy. We will describe recent evidence suggesting high p38/ERK ratio, bone morphogenetic proteins, and tumor growth factor-beta 2 promote dormancy in solid tumors. Furthermore, we will discuss the possible regulation of dormancy by hematopoietic stem cell and vascular niches, and describe novel models recapitulating bone marrow metastatic latency and out- growth, 3D microvascular networks, and 3D biomatrix supportive niches in the studies of tumor cell dormancy.

Entities:  

Mesh:

Year:  2014        PMID: 24847652      PMCID: PMC4412595          DOI: 10.1016/j.ddtec.2014.02.002

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  38 in total

Review 1.  Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases.

Authors:  Martine P Roudier; Eva Corey; Lawrence D True; Celestia S Hiagno; Susan M Ott; Robert L Vessell
Journal:  Cancer Treat Res       Date:  2004

Review 2.  Tumor dormancy and immunoescape.

Authors:  Bruno Quesnel
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 3.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

Review 4.  Controversies in clinical cancer dormancy.

Authors:  Jonathan W Uhr; Klaus Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

5.  Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.

Authors:  Deborah A Ahove; Karen E Hoffman; Jim C Hu; Toni K Choueiri; Anthony V D'Amico; Paul L Nguyen
Journal:  Urology       Date:  2010-08-14       Impact factor: 2.649

6.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

7.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Aaron M Havens; Younghun Jung; Anjali Mishra; Jeena Joseph; Jin Koo Kim; Lalit R Patel; Chi Ying; Anne M Ziegler; Michael J Pienta; Junhui Song; Jingcheng Wang; Robert D Loberg; Paul H Krebsbach; Kenneth J Pienta; Russell S Taichman
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

8.  Detection and isolation of prostate cancer cells from peripheral blood and bone marrow.

Authors:  William J Ellis; Jesco Pfitzenmaier; Janet Colli; Edward Arfman; Paul H Lange; Robert L Vessella
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

9.  Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Authors:  Dorothea Weckermann; Bernhard Polzer; Thomas Ragg; Andreas Blana; Günter Schlimok; Hans Arnholdt; Simone Bertz; Rolf Harzmann; Christoph A Klein
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

10.  Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.

Authors:  Malgorzata Banys; Erich-Franz Solomayer; Gerhard Gebauer; Wolfgang Janni; Natalia Krawczyk; Hans-Joachim Lueck; Sven Becker; Jens Huober; Bernhard Kraemer; Birgit Wackwitz; Peter Hirnle; Diethelm Wallwiener; Tanja Fehm
Journal:  BMC Cancer       Date:  2013-10-15       Impact factor: 4.430

View more
  14 in total

Review 1.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 2.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

Review 3.  Disseminated tumor cells and dormancy in prostate cancer metastasis.

Authors:  Emma E van der Toom; James E Verdone; Kenneth J Pienta
Journal:  Curr Opin Biotechnol       Date:  2016-02-20       Impact factor: 9.740

Review 4.  Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

Authors:  Sun H Park; Evan T Keller; Yusuke Shiozawa
Journal:  Calcif Tissue Int       Date:  2017-11-01       Impact factor: 4.333

Review 5.  Current and emerging therapies for bone metastatic castration-resistant prostate cancer.

Authors:  Jeremy S Frieling; David Basanta; Conor C Lynch
Journal:  Cancer Control       Date:  2015-01       Impact factor: 3.302

6.  Parallel-Reaction-Monitoring-Based Proteome-Wide Profiling of Differential Kinase Protein Expression during Prostate Cancer Metastasis in Vitro.

Authors:  Weili Miao; Jun Yuan; Lin Li; Yinsheng Wang
Journal:  Anal Chem       Date:  2019-07-10       Impact factor: 6.986

7.  Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

Authors:  Nazanin Ruppender; Sandy Larson; Bryce Lakely; Lori Kollath; Lisha Brown; Ilsa Coleman; Roger Coleman; Holly Nguyen; Peter S Nelson; Eva Corey; Linda A Snyder; Robert L Vessella; Colm Morrissey; Hung-Ming Lam
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

Review 8.  Cancer Cell Colonisation in the Bone Microenvironment.

Authors:  Casina Kan; Geoffrey Vargas; François Le Pape; Philippe Clézardin
Journal:  Int J Mol Sci       Date:  2016-10-04       Impact factor: 5.923

9.  Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells.

Authors:  Rie Nakata; Hiroyuki Shimada; G Esteban Fernandez; Rob Fanter; Muller Fabbri; Jemily Malvar; Pascale Zimmermann; Yves A DeClerck
Journal:  J Extracell Vesicles       Date:  2017-06-25

Review 10.  Technical challenges in the isolation and analysis of circulating tumor cells.

Authors:  Emma E van der Toom; James E Verdone; Michael A Gorin; Kenneth J Pienta
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.